Our findings demonstrate the utility of an ASO-based approach to treat retinal dysfunction in CLN3 Batten disease and support broader ASO applications for treating ocular diseases. The gene discussed is CLN3; the disease is juvenile neuronal ceroid lipofuscinosis.